Enovis Corporation (NYSE:ENOV – Get Free Report)’s stock price was down 5.6% during trading on Thursday . The stock traded as low as $25.26 and last traded at $24.9690. Approximately 373,186 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 1,039,166 shares. The stock had previously closed at $26.46.
Analyst Ratings Changes
Several research firms have weighed in on ENOV. Evercore reiterated an “outperform” rating and set a $36.00 price objective on shares of Enovis in a research report on Friday, May 8th. Wells Fargo & Company reduced their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. William Blair initiated coverage on Enovis in a research report on Friday, April 17th. They issued an “outperform” rating for the company. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, BTIG Research upped their price target on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $45.17.
Get Our Latest Report on Enovis
Enovis Stock Down 7.0%
Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts forecast that Enovis Corporation will post 3.65 EPS for the current fiscal year.
Insider Activity at Enovis
In other Enovis news, insider Oliver Engert purchased 1,000 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were acquired at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the acquisition, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have acquired 5,000 shares of company stock worth $121,983. Corporate insiders own 2.90% of the company’s stock.
Institutional Investors Weigh In On Enovis
A number of large investors have recently bought and sold shares of the business. Front Street Capital Management Inc. raised its holdings in Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares in the last quarter. Amundi boosted its stake in shares of Enovis by 2.3% during the 1st quarter. Amundi now owns 74,184 shares of the company’s stock worth $1,688,000 after acquiring an additional 1,677 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Enovis by 38.9% during the 1st quarter. California State Teachers Retirement System now owns 76,966 shares of the company’s stock valued at $1,751,000 after acquiring an additional 21,571 shares during the last quarter. Quantinno Capital Management LP increased its holdings in shares of Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after acquiring an additional 342,556 shares during the last quarter. Finally, London Co. of Virginia raised its stake in shares of Enovis by 12.0% in the 1st quarter. London Co. of Virginia now owns 416,582 shares of the company’s stock valued at $9,477,000 after acquiring an additional 44,610 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.
Enovis Company Profile
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Read More
- Five stocks we like better than Enovis
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
